Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study

ABSTRACT Background Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited. Methods A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index mortality data for patients initiating nivolumab monotherapy during 2019–2023. Overall survival (OS), time to treatment discontinuation (TTD), and dispensing‐based proxies for potential immune‐related adverse events (irAEs) were assessed. Results Among 1398 patients, median OS was 9.3 months and TTD was 7.8 months. Median OS was longer in males than females (10.0 vs. 7.7 months, p = 0.049), while patients with prior corticosteroid exposure had shorter OS than those without (8.3 vs. 11.5 months; aHR 1.20, 95% CI: 1.06–1.36). Incident corticosteroid and levothyroxine use occurred in 10.3% and 10.9% of patients, respectively. Conclusions Real‐world outcomes were comparable to clinical trial findings, supporting nivolumab's effectiveness in Australian clinical practice.

Authors

Institutions

Publication Details

Journal
Head & Neck
Published
2026-11-14
DOI
https://doi.org/10.1002/hed.70547
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study

Chin Hang Yiu, Edwin C.K. Tan, Christine Y. Lu, Phoebe L. Sault
Head & Neck
Cancer Immunotherapy and Biomarkers
article

Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study

Chin Hang Yiu, Edwin C.K. Tan, Christine Y. Lu, Phoebe L. Sault
article en

Abstract

ABSTRACT Background Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited. Methods A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index mortality data for patients initiating nivolumab monotherapy during 2019–2023. Overall survival (OS), time to treatment discontinuation (TTD), and dispensing‐based proxies for potential immune‐related adverse events (irAEs) were assessed. Results Among 1398 patients, median OS was 9.3 months and TTD was 7.8 months. Median OS was longer in males than females (10.0 vs. 7.7 months, p = 0.049), while patients with prior corticosteroid exposure had shorter OS than those without (8.3 vs. 11.5 months; aHR 1.20, 95% CI: 1.06–1.36). Incident corticosteroid and levothyroxine use occurred in 10.3% and 10.9% of patients, respectively. Conclusions Real‐world outcomes were comparable to clinical trial findings, supporting nivolumab's effectiveness in Australian clinical practice.

Head & Neck
The University of Sydney (AU), Royal North Shore Hospital (AU), Cooperative Trials Group for Neuro-Oncology (AU), Northern Sydney Local Health District (AU)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon